Navigation Links
Surveyed Oncologists Expect to Prescribe Provenge to about Half of Their Prostate Cancer Patients if the Vaccine is Approved

WALTHAM, Mass., July 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, if Dendreon's Provenge receives regulatory approval, surveyed oncologists expect to prescribe Provenge to 54 percent of patients with asymptomatic hormone refractory metastatic prostate cancer. Due to the side effects associated with currently available chemotherapy, most oncologists recommend that men who have stopped responding to hormone therapy wait for the development of symptoms before starting chemotherapy.

The new Physician & Payer Forum report entitled Clinician and Payer Attitudes Toward Emerging Cancer Vaccines for Prostate Cancer, Lung Cancer, and Glioma finds that clinicians are willing to prescribe Provenge to patients in the absence of symptoms. The report also finds that three-quarters of surveyed oncologists and urologists consider Provenge a major breakthrough in the treatment of prostate cancer. Additionally, 89 percent of surveyed urologists expect to prescribe Provenge for prostate cancer.

"Treatment rates for advanced prostate cancer will be boosted by an effective vaccine which also carries a benign side effect profile," said Decision Resources Analyst Marcus Hoyle. "Surveyed clinicians indicate they are very encouraged by the fact that, in a Phase III clinical trial, Provenge demonstrated an improvement in median overall survival in prostate cancer patients."

In addition to Provenge, other therapeutic vaccines in development for cancer include Merck KGaA's Stimuvax for non-small-cell lung cancer and Celldex Therapeutics/Pfizer's CDX-110 for glioblastoma multiforme (glioma). Surveyed experts consider both drugs to be the most promising therapeutic vaccines for the treatment of these two diseases, owing to an impressive effect on overall survival in Phase II clinical trials.

Therapeutic cancer vaccines are likely to command a high price. Although most surveyed clinicians expect to prescribe these agents, a minority of surveyed managed care organizations' (MCO) pharmacy directors expect to place Provenge, Stimuvax and CDX-110 on the top two tiers of their formularies. Only 25 percent of surveyed MCOs expect to place Provenge on tier one or tier two of their formularies, assuming the vaccine is priced in line with Roche/Chugai's Avastin. Additionally, of surveyed MCOs, 30 percent expect to place Stimuvax on the top two tiers of their formularies and 35 percent expect to place CDX-110 on the top two tiers of their formularies.

Clinician and Payer Attitudes Toward Emerging Cancer Vaccines for Prostate Cancer, Lung Cancer, and Glioma is based on a U.S. survey of 70 oncologists, 71 urologists and 20 MCO pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or

registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                              Decision Resources, Inc.
    Christopher Comfort                             Elizabeth Marshall
    781-296-2597                                    781-296-2563               

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. For Treatment of Rheumatoid Arthritis, Surveyed Rheumatologists and Patients Differ In Their Perception of Bristol-Myers Squibbs Orencia
2. For Treatment of Type 2 Diabetes, 89 Percent of Surveyed Endocrinologists Identify a Need for Additional GLP-1 Analogues and 71 Percent Say the Same About DPP-IV Inhibitors
3. For Treatment of Dyslipidemia, Surveyed Physicians are Increasingly Switching Patients to a More Potent Statin Following the ENHANCE and SEAS Trials
4. Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infections in the Hospital Setting
5. Surveyed Psychiatrists and PCPs Expect to Increase Their First-Line Use of SNRIs Over the Next Two Years for the Treatment of Generalized Anxiety Disorder
6. For Alzheimers Disease, Surveyed Neurologists Identify a Therapys Effect on Cognitive Decline as the Attribute That Most Influences Their Prescribing Decisions
7. For Bipolar Depression, Surveyed Experts Indicate That Current and Emerging Therapies Have No Advantage Over Seroquel in Decreasing the Severity of Symptoms
8. Surveyed Experts Indicate That the Combination of Sutent and Taxol Has Advantages Over the Combination of Avastin and Taxol in the Treatment of Metastatic Triple-Negative Breast Cancer
9. Surveyed Specialists Foresee Greater Use of Parenteral Outpatient Therapy for the Treatment of Osteomyelitis
10. For Atrial Fibrillation, Surveyed Experts Indicate That Multaq, Celivarone and ATI-2042 Have Advantages Over Propafenone in the Maintenance of Normal Sinus Rhythm
11. For Ulcerative Colitis, Surveyed Experts Indicate That Corticosteroids Have Advantages Over Remicade in the Induction of Remission
Post Your Comments:
(Date:11/24/2015)... ... ... Charitable giving is at its peak during the holidays. In fact, ... the year totalling over $358 billion in 2014. With more than 1.5 million ... individuals who want to “give back” during the holidays. , “With so many charities ...
(Date:11/24/2015)... ... November 24, 2015 , ... The hospitals ... to several aspects of orthopedic care. They have received recognition for excellence from ... orthopedic care. , Becker's Hospital Review selected hospitals for inclusion based on ...
(Date:11/24/2015)... Port Richey, FL (PRWEB) , ... November 24, 2015 , ... ... it deems a growing epidemic as deaths from prescription opioids in the United States ... heroin and cocaine. In 2013 alone, opioids were involved in 37 percent of all ...
(Date:11/24/2015)... ... November 24, 2015 , ... Serenity Point Rehabilitation, a holistic treatment center for ... with some of the staff members at their recovery center. The videos highlight some ... as some of the things that make their recovery program so unique. , “Making ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... award at Cleveland University-Kansas City (CU-KC), in Overland Park, Kansas. Benson, ... Chiropractor and University President Carl S. Cleveland III on October 16. , “Katie ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... Nov. 24, 2015  Natera, Inc. (Nasdaq: ... genetic testing and the analysis of circulating ... present at the 27 th  Annual Piper ... 2015 at 1:00 p.m. ET.  Matthew Rabinowitz, Ph.D., CEO of ... business activities and financial outlook. ...
(Date:11/24/2015)... York , 24 de noviembre de 2015 ... Avery Breathing Pacemaker System, se complace anunciar el ... como consultor clínico.   ... Foto -   ... es un fisiólogo y consultor en neonatología y ...
(Date:11/24/2015)... Connecticut , November 24, 2015 ... of Acadiana has entered into a multi-year agreement ... imaging centers. This investment will provide the Breast Center ... --> Sectra (STO: SECT B) announces that ... agreement to deploy Breast Imaging PACS in its ...
Breaking Medicine Technology: